The French drug giant Sanofi on Thursday reported positive results in a study of its new pill to treat multiple sclerosis.
The drug, which Sanofi licensed from South San Francisco-based Principia Biopharma in 2017, “significantly reduced disease activity associated with multiple sclerosis as measured by magnetic resonance imaging,” the company said in a statement. Full data on the drug, called SAR442168, are not being made available yet, but will be presented at a later medical meeting.
The drug is designed to be different than existing treatments for the disease because it can enter the brain. In multiple sclerosis, the immune system attacks nerve cells in the brain and spinal cord; current treatments may have trouble protecting brain cells.
About the Author Reprints
